novel reversible anticoagualtion - RNA aptamers - anti FIX

RADAR: First significant clinical use of novel reversible anticoagulation system

April 6, 2011 | Sue Hughes

New Orleans, LA - A phase 2 trial of a novel anticoagulation system that involves first giving a factor IX inhibitor and then administering a reversal agent has shown preliminary encouraging results, albeit with a question about potential allergic reactions.

REG1 (Regado Biosciences) consists of an RNA aptamer of factor IX—pegnivacogin—which binds to and inhibits the factor IX molecule for a 24-hour duration, and the reversal agent—anivamersen, which binds to and inactivates pegnivacogin.

from heart.org

http://www.springerlink.com/content/e2624407h271h2k2/fulltext.pdf